- Home
- FNLC vs LRMR Comparison
FNLC vs LRMR Comparison
Compare FNLC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | LRMR |
|---|---|---|
| Founded | 1864 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.1M | 455.8M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FNLC | LRMR |
|---|---|---|
| Price | $34.53 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 20.1K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | ★ 26.34 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | $20.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.13 | $2.72 |
| 52 Week High | $36.30 | $6.42 |
Technical Indicators
Market Signals| Indicator | FNLC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 49.25 |
| Support Level | $32.73 | $3.49 |
| Resistance Level | $36.08 | $4.21 |
| Average True Range (ATR) | 0.66 | 0.19 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 31.99 | 21.50 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.